<DOC>
	<DOCNO>NCT00083278</DOCNO>
	<brief_summary>This Phase II study design treat patient diagnose Stage IV Breast Cancer , progress despite treatment primary therapy , include hormonal therapy , chemotherapy , antibody therapy . Thirty-three patient treat monoclonal antibody MDX-010 . The initial antitumor activity profile MDX-010 determine , well identification induction antitumor immunity follow MDX-010 treatment .</brief_summary>
	<brief_title>Study MDX-010 Stage IV Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Provide write informed consent diagnose Stage IV adenocarcinoma progress despite previous therapy least 18 year age measurable disease define RECIST must discontinue alternative therapy use treat breast cancer least 4 week prior enrollment agree use therapy duration study ( patient may continue receive tamoxifen , bisphosphate therapy trastuzumab ) prior radiation must complete least 4 week prior enrollment ECOG performance status 02 Negative pregnancy test Screening lab value must meet must disease free cancer least 5 year symptomatic untreated brain metastasis active history autoimmune disease active HIV , HTLV , HBV HCV infection concurrent medical condition require use systemic corticosteroid , must discontinue least 4 week prior enrollment prior therapy antiCTLA4 antibody significant organ compromise , uncontrolled heart , liver , lung , renal disease serious illness pregnancy nursing</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Stage IV adenocarcinoma breast</keyword>
</DOC>